OTUB1 (NM_017670) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC210648L2V
- LentiORF®
Lenti ORF particles, OTUB1 (mGFP-tagged) - Human OTU domain, ubiquitin aldehyde binding 1 (OTUB1), transcript variant 1, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 9,120.00
Product images
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | OTUB1 (NM_017670) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | HSPC263; OTB1; OTU1 |
Vector | pLenti-C-mGFP |
ACCN | NM_017670 |
ORF Size | 813 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC210648).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_017670.1 |
RefSeq Size | 2310 bp |
RefSeq ORF | 816 bp |
Locus ID | 55611 |
Protein Families | Protease |
MW | 31.3 kDa |
Gene Summary | The product of this gene is a member of the OTU (ovarian tumor) superfamily of predicted cysteine proteases. The encoded protein is a highly specific ubiquitin iso-peptidase, and cleaves ubiquitin from branched poly-ubiquitin chains but not from ubiquitinated substrates. It interacts with another ubiquitin protease and an E3 ubiquitin ligase that inhibits cytokine gene transcription in the immune system. It is proposed to function in specific ubiquitin-dependent pathways, possibly by providing an editing function for polyubiquitin chain growth. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2008] |
Documents
Product Manuals |
FAQs |
SDS |